Immunovia to host a webcast with the chance to study extra concerning the optimistic scientific validation of its next-generation pancreatic most cancers check By Investing.com

LUND, Sweden, Dec. 16, 2024 /PRNewswire/ — Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic most cancers diagnostics firm, revealed optimistic leads to the scientific validation of its next-generation check for pancreatic most cancers on December 9, 2024. As a observe up, Immunovia will host a webcast on Tuesday, December 17 at 3 pm CET.

Jeff Borcherding, CEO, Norma Alonzo Palma, PhD, VP Medical and Medical (TASE:) Affairs and Lisa Ford (NYSE:), PhD, Laboratory Director will current extra particulars concerning the outcomes and the implications of the examine. Dr. Aimee Lucas, Chief of Gastroenterology & Hepatology at Mount Sinai and Professor of Drugs Icahn Faculty of Drugs, will be part of the webcast to share perspective on the examine end result. The webcast will likely be held in English and can supply attendees the chance to ask questions. You’re welcome to affix, see particulars under.

Hyperlink to the webcast: https://hyperlink.edgepilot.com/s/e8dd2ee9/T5WEGMPm6EqzxajKwPwQbw?u=https://creo-live.creomediamanager.com/dd81645b-30e0-45e1-af83-75a059fcba71

A recording of the presentation will likely be out there on Immunovia’s web site.

For extra data, please contact:
Karin Almqvist Liwendahl
Chief Monetary Officer
[email protected]

Immunovia in short

Immunovia AB is a diagnostic firm whose mission is to extend survival charges for sufferers with pancreatic most cancers by way of early detection. Immunovia is targeted on the event and commercialization of straightforward blood-based testing to detect proteins and antibodies that point out a high-risk particular person has developed pancreatic most cancers.

Immunovia collaborates and engages with healthcare suppliers, main consultants and affected person advocacy teams to make its check out there to people at elevated threat for pancreatic most cancers.

USA is the world’s largest marketplace for detection of pancreatic most cancers. The corporate estimates that within the USA, 1.8 million people are at high-risk for pancreatic most cancers and may benefit from annual surveillance testing.

Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For extra data, please go to  www.immunovia.com

This data was delivered to you by Cision http://information.cision.com

https://information.cision.com/immunovia-ab/r/immunovia-to-host-a-webcast-with-the-opportunity-to-learn-more-about-the-positive-clinical-validatio,c4082507

The next information can be found for obtain: